JACC: Cardiovascular Imaging
Volume 2, Issue 2 , Pages 187-198 , February 2009

Molecular Imaging for Efficacy of Pharmacologic Intervention in Myocardial Remodeling

  • Susanne W.M. van den Borne, MD

      Affiliations

    • Division of Cardiology and Department of Pathology, University of California, Irvine School of Medicine, Irvine, California
    • Department of Cardiology, Biochemistry, Pathology and Pharmacology, University Hospital Maastricht, Maastricht, the Netherlands
    • ,
  • Satoshi Isobe, MD, PhD

      Affiliations

    • Division of Cardiology and Department of Pathology, University of California, Irvine School of Medicine, Irvine, California
    • ,
  • H. Reinier Zandbergen, MD

      Affiliations

    • Department of Cardiology, Biochemistry, Pathology and Pharmacology, University Hospital Maastricht, Maastricht, the Netherlands
    • ,
  • Peng Li, MD, PhD

      Affiliations

    • Division of Cardiology and Department of Pathology, University of California, Irvine School of Medicine, Irvine, California
    • ,
  • Artiom Petrov, PhD

      Affiliations

    • Division of Cardiology and Department of Pathology, University of California, Irvine School of Medicine, Irvine, California
    • ,
  • Nathan D. Wong, PhD, FACC

      Affiliations

    • Division of Cardiology and Department of Pathology, University of California, Irvine School of Medicine, Irvine, California
    • ,
  • Shinichiro Fujimoto, MD, PhD

      Affiliations

    • Division of Cardiology and Department of Pathology, University of California, Irvine School of Medicine, Irvine, California
    • ,
  • Ai Fujimoto, MD, PhD

      Affiliations

    • Division of Cardiology and Department of Pathology, University of California, Irvine School of Medicine, Irvine, California
    • ,
  • Dagfinn Lovhaug, PhD

      Affiliations

    • GE Healthcare, AS, Oslo, Norway
    • ,
  • Jos F.M. Smits, PhD

      Affiliations

    • Department of Cardiology, Biochemistry, Pathology and Pharmacology, University Hospital Maastricht, Maastricht, the Netherlands
    • ,
  • Mat J.A.P. Daemen, MD, PhD

      Affiliations

    • Department of Cardiology, Biochemistry, Pathology and Pharmacology, University Hospital Maastricht, Maastricht, the Netherlands
    • ,
  • W. Matthijs Blankesteijn, PhD

      Affiliations

    • Department of Cardiology, Biochemistry, Pathology and Pharmacology, University Hospital Maastricht, Maastricht, the Netherlands
    • ,
  • Chris Reutelingsperger, PhD

      Affiliations

    • Department of Cardiology, Biochemistry, Pathology and Pharmacology, University Hospital Maastricht, Maastricht, the Netherlands
    • ,
  • Faiez Zannad, MD, PhD, FACC

      Affiliations

    • University Henri Poincaré, Nancy, France
    • ,
  • Navneet Narula, MD

      Affiliations

    • Division of Cardiology and Department of Pathology, University of California, Irvine School of Medicine, Irvine, California
    • ,
  • Mani A. Vannan, MD, FACC

      Affiliations

    • Division of Cardiology and Department of Pathology, University of California, Irvine School of Medicine, Irvine, California
    • ,
  • Bertram Pitt, MD, FACC

      Affiliations

    • Division of Cardiology, University of Michigan, Ann Arbor, Michigan
    • ,
  • Leonard Hofstra, MD, PhD

      Affiliations

    • Department of Cardiology, Biochemistry, Pathology and Pharmacology, University Hospital Maastricht, Maastricht, the Netherlands
    • ,
  • Jagat Narula, MD, PhD, FACC

      Affiliations

    • Division of Cardiology and Department of Pathology, University of California, Irvine School of Medicine, Irvine, California
    • Corresponding Author InformationReprint requests and correspondence: Dr. Jagat Narula, Division of Cardiology, University of California, Irvine School of Medicine, UCI Main Campus, Medical-Science Building I, Room C 112, Irvine, California 92697

Received 9 June 2008 ,Revised 31 October 2008 ,Accepted 6 November 2008.

References 

  1. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium (Fibrosis and renin-angiotensin-aldosterone system). Circulation. 1991;83:1849–1865
  2. Weber KT, Anversa P, Armstrong PW, et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 1992;20:3–16
  3. Pitt B. Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation. 2003;108:1790–1794
  4. Shirani J, Narula J, Eckelman WC, Narula N, Dilsizian V. Early imaging in heart failure: exploring novel molecular targets. J Nucl Cardiol. 2007;14:100–110
  5. Volders PG, Willems IE, Cleutjens JP, Arends JW, Havenith MG, Daemen MJ. Interstitial collagen is increased in the non-infarcted human myocardium after myocardial infarction. J Mol Cell Cardiol. 1993;25:1317–1323
  6. Cleutjens JP, Blankesteijn WM, Daemen MJ, Smits JF. The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res. 1999;44:232–241
  7. Anversa P, Capasso JM. Cardiac hypertrophy and ventricular remodeling. Lab Invest. 1991;64:441–445
  8. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–1587
  9. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure (Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)). N Engl J Med. 1987;316:1429–1435
  10. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–310
  11. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure (Randomized Aldactone Evaluation Study Investigators). N Engl J Med. 1999;341:709–717
  12. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (The Heart Outcomes Prevention Evaluation Study Investigators). N Engl J Med. 2000;342:145–153
  13. Pfeffer MA, Braunwald E, Moye LA, et al. The SAVE Investigators Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction (Results of the survival and ventricular enlargement trial). N Engl J Med. 1992;327:669–677
  14. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302
  15. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  16. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–766
  17. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675
  18. McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation. 2001;103:1644–1648
  19. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002;347:1135–1142
  20. van den Borne SWM, Isobe S, Verjans J, et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol. 2008;52:2017–2028
  21. Verjans JWH, Lovhaug D, Narula N, et al. Noninvasive imaging of angiotensin receptores after myocardial infarction. J Am Coll Cardiol Cardiovasc Imaging. 2008;1:354–362
  22. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography (American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms). J Am Soc Echocardiogr. 1989;2:358–367
  23. Tonti G, Verjans J, Pedrizzetti G, et al. Measurement of apical torsion in mitochrondrial cardiomyopathy using a novel B-mode, automated tracking algorithm. J Am Coll Cardiol. 2005;45:305A
  24. Whittaker P, Kloner RA, Boughner DR, Pickering JG. Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol. 1994;89:397–410
  25. MacKenna DA, Omens JH, McCulloch AD, Covell JW. Contribution of collagen matrix to passive left ventricular mechanics in isolated rat hearts. Am J Physiol. 1994;266:H1007–H1018
  26. Verjans JW, Wolters SL, Lax M, et al. Imaging avb3/b5 Integrin Upregulation in Patients After Myocardial Infarction. Circulation. 2007;116:II3288
  27. Poulsen SH, Host NB, Jensen SE, Egstrup K. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation. 2000;101:1527–1532
  28. Cicoira M, Rossi A, Bonapace S, et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail. 2004;10:403–411
  29. Radovan J, Vaclav P, Petr W, et al. Changes of collagen metabolism predict the left ventricular remodeling after myocardial infarction. Mol Cell Biochem. 2006;293:71–78
  30. Zannad F, Alla F, Dousset B, Perez A, Pitt B Rales Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation. 2000;102:2700–2706
  31. Zannad F, Radauceanu A. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. Heart Fail Rev. 2005;10:71–78
  32. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767–771
  33. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559
  34. van Amerongen MJ, Harmsen MC, van Rooijen N, Petersen AH, van Luyn MJ. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol. 2007;170:818–829
  35. Dai W, Wold LE, Dow JS, Kloner RA. Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. J Am Coll Cardiol. 2005;46:714–719

 Dr. van den Borne was partially supported by a grant from the Netherlands Heart Foundation (2006R013). Dr. Lovhaug is an employee of GE Healthcare, involved in tracer preparation for the imaging studies. Dr. Pitt is a consultant to Pfizer, Merck, Takeda, Astra Zeneca, Synvista, Novartis, and Nile therapeutics but has no conflicts directly with the project. H. William Strauss, MD, acted as Guest Editor for this paper.

PII: S1936-878X(08)00517-2

doi: 10.1016/j.jcmg.2008.11.011

JACC: Cardiovascular Imaging
Volume 2, Issue 2 , Pages 187-198 , February 2009

Article Tools

* Image Usage & Resolution